Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
MyoKardia, Inc., announced its participation in the following upcoming investor conferences:
The first half of the year has been characterized by continued work to develop the company’s innovative projects in two treatment areas, both of which have significant medical needs because the current treatment options are less effective or non-existent.
TLC announced that the management team is scheduled to present at the two upcoming investor conferences
The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014
Investment in life sciences innovation at all-time high, driving demand for new real estate concepts
U.S. biopharmaceutical research and development spending reached a record $179 billion in 2018 and is expected to grow by $34 billion by 2024, an indication that companies are investing now to improve their future pipelines, according to JLL’s eighth annual Life Sciences Outlook.
“This transaction advances Zogenix’s mission to become a leading rare disease pharmaceutical company by adding MT1621 to our pipeline of late-stage Fintepla programs,” stated Stephen J. Farr, president and chief executive officer of Zogenix.
Resverlogix Corp. announced that its Annual and Special Meeting of Shareholders is to be held Thursday, October 31, 2019 at Mount Royal University, Roderick Mah Centre for Continuous Learning – Ross Glen Hall, 4825 Mount Royal Gate SW, Calgary, Alberta, commencing at approximately 1:00 pm.
Zenith Capital Corp. announced that its Annual and Special Meeting of Shareholders is to be held Thursday, October 31, 2019 at Mount Royal University, Roderick Mah Centre for Continuous Learning – Ross Glen Hall, 4825 Mount Royal Gate SW, Calgary, Alberta.
A report on the freeze & thaw systems market which considers the global industry analysis 2014 – 2018 and forecast 2019-2029 projects that, the freeze & thaw systems market is expected to reach ~ US$ 270 Mn by the end of 2019 in terms of value, and is forecasted to reach ~ US$ 550 Bn by the end of 2029.
Fusion Antibodies plc, specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, confirms that the Annual Report and Accounts for the year ended 31 March 2019, the Notice of Annual General Meeting and a Form of Proxy will be posted to shareholders later.